Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Eli Lilly And Company patents


Recent patent applications related to Eli Lilly And Company. Eli Lilly And Company is listed as an Agent/Assignee. Note: Eli Lilly And Company may have other listings under different names/spellings. We're not affiliated with Eli Lilly And Company, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "E" | Eli Lilly And Company-related inventors


Novel carboxylic acid compounds useful for inhibiting microsomal prostaglandin e2 synthase-1

. . The present invention provides compounds of formula 1, or a pharmaceutically acceptable salts, thereof, where r, x, a, e, and g are as described herein, methods of preparing the compounds, and use of the compounds to treat pain and/or inflammation.. . ... Eli Lilly And Company

Zero position sensing system for medication delivery device

A sensing system for determining a zero position of a medication delivery device. The sensing system includes at least one actuator member, a biasing member, a stop surface and a sensor. ... Eli Lilly And Company

Process development of a pyridine-containing nk-1 receptor antagonist

The disclosure provides process developments and novel routes for the preparation of the nk-1 receptor antagonist, compound (i) and intermediates in those routes.. . ... Eli Lilly And Company

5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1h-pyrazol-3-ylamino)pyrazine-2-carbonitrile (s)-lactate monohydrate

. . The disclosure herein includes 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1h-pyrazol-3-ylamino)pyrazine-2-carbonitrile (s)-lactate monohydrate that inhibits chk1/2 and is useful in the treatment of cancer.. . ... Eli Lilly And Company

Treatment of pruritus

. . The present invention provides a method using il-17 antagonistic antibodies for treating pruritus.. . ... Eli Lilly And Company

Fusion proteins

. . The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human igg fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.. ... Eli Lilly And Company

Rapid-acting insulin compositions

The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.. . ... Eli Lilly And Company

Anti-cgrp antibody formulation

Pharmaceutical formulations for anti-cgrp antibodies, and methods of using the same, are provided which are useful as treatment for migraines, episodic headaches, chronic headaches, chronic cluster headaches, and episodic cluster headaches.. . ... Eli Lilly And Company

Processes and intermediates for the preparation of {1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile

The present invention provides processes and intermediates for the preparation of {1-(ethylsulfonyl)-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]azetidin-3-yl}acetonitrile: (i). . ... Eli Lilly And Company

Anti-dkk-1-anti-rankl bispecific antibody compounds

Bispecific antibody compounds, and methods of using same, are provided which bind and neutralize dkk-1 and rankl and which are useful as adjuncts to spinal fusion surgery or as agents for bone healing or treating conditions associated with bone loss or degeneration.. . ... Eli Lilly And Company

Anti-il-33 antibodies and uses thereof

Antibodies which bind and neutralize human il-33, and methods of using same, are provided, said antibodies are useful as agents for treating conditions associated with allergic disease including treating atopic dermatitis.. . ... Eli Lilly And Company

7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant idh1 inhibitors

Phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds of formula i, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.. . ... Eli Lilly And Company

Tgfbeta receptor ii antibodies

The present invention relates to antibodies that bind tgfβ receptor ii (tgfβrii), and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.. . ... Eli Lilly And Company

Glucagon receptor agonists

The present invention relates to compounds with an extended duration of action at the glucagon receptor as compared to native glucagon. Specifically provided are glucagon receptor agonists with modifications to the structure of native glucagon introduced to selectively agonize the glucagon receptor over an extended period of time.. ... Eli Lilly And Company

04/19/18 / #20180104254

Targeted treatment of leiomyosarcoma

A method and medicament comprising 4,4,4-trifluoro-n-[(1s)-2-[[(7s)-5-(2-hydroxyethyl)-6-oxo-7h-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof for treating leiomyosarcoma is provided.. . ... Eli Lilly And Company

04/19/18 / #20180104234

Combination therapy for cancer

The present invention provides a method of treating squamous histology cancers and pi3k pathway activated large cell lung and colorectal cancers in a patient comprising administering to a patient in need of such treatment an effective amount of 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2s)-2-methoxypropyl]-3-methyl-1,3-dihydro-2h-imidazo[4,5-c]quinolin-2-one, or a pharmaceutically acceptable salt thereof; in combination with an effective amount of necitumumab.. . ... Eli Lilly And Company

03/29/18 / #20180086732

Ghrelin 0-acyl transferase inhibitors

. . The present invention provides novel goat inhibitors and their salts and pharmaceutical compositions thereof.. . ... Eli Lilly And Company

03/22/18 / #20180079729

Ghrelin 0-acyl transferase inhibitors

The present invention provides novel goat inhibitors and their salts and pharmaceutical compositions thereof.. . ... Eli Lilly And Company

03/08/18 / #20180064882

Dispensing device with drive mechanism having converging ramps

A dispensing device for dispensing medication from a medication container. The dispensing device includes a housing, a drive member engageable with the medication container, at least one first ramp surface fixed relative to the housing, a driver movable within the housing to move the drive member for forcing medication from the medication container, the driver including at least one second ramp surface, and a plunger including at least one push module movable relative to the housing from a ready position to a plunged position. ... Eli Lilly And Company

03/01/18 / #20180057591

Anti-tim-3 antibodies

. . The present invention relates to antibodies that bind human t-cell immunoglobulin- and mucin-domain-containing protein-3 (tim-3), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.. . ... Eli Lilly And Company

03/01/18 / #20180057584

Il-17 antibody formulation

The present invention provides pharmaceutical formulations for anti-il-17 antibodies. These anti-il-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing psoriatic arthritis or multiple myeloma.. ... Eli Lilly And Company

02/15/18 / #20180042888

Monensin water dispersible granules by wet granulation

The present disclosure provides a water dispersible granule formulation comprising from about 5% to about 80% (w/w) of monensin; from about 1% to about 20% (w/w) of one or more surfactants; from about 1% to about 30% (w/w) of one or more binders; from about 1% to about 90% (w/w) of one or more fillers; and water up to about 2% (w/w). The present disclosure also provides a process for the preparation of a water dispersible monensin granule formulation. ... Eli Lilly And Company

02/01/18 / #20180030044

Selective bace1 inhibitors

The present invention provides a compound of formula i: or a pharmaceutically acceptable salt thereof.. . ... Eli Lilly And Company

01/04/18 / #20180000904

Nasal powder formulation for treatment of hypoglycemia

. . The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.. ... Eli Lilly And Company

12/28/17 / #20170368071

Tosylate salt of n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide

The present invention provides a tosylate salt of n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide.. . ... Eli Lilly And Company

12/21/17 / #20170362315

Pan-elr+ cxc chemokine antibodies

Antibodies are provided that specifically bind seven human elr+ cxc chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (ibd), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.. ... Eli Lilly And Company

12/14/17 / #20170354790

Needle shield puller cap assembly

A puller assembly for removing a shield from around a needle of a syringe. The puller assembly includes a grip component and a cap. ... Eli Lilly And Company

12/14/17 / #20170354779

Automatic medication injection device with audible indication of injecting progress

An automatic medication injection device that provides a user with audible notice of injecting progress. The device in one form includes a plurality of sound elements located on drive mechanism portion that inserts within a barrel of a container of medication to advance a sealing plunger of that container. ... Eli Lilly And Company

12/14/17 / #20170354645

Methods for treating kidney disorders

Provided are methods and formulations for treating kidney disorders in man and animals, which include the use of a compound of the formula i and pharmaceutically acceptable salts thereof.. . ... Eli Lilly And Company

12/14/17 / #20170354641

2,3-dihydro-1h-indole compounds

The present invention relates to certain novel 2,3-dihydro-1h-indole compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, more particularly for the treatment of cancer selected from the group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, colorectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid cancer, glioma, non-hodgkin's lymphoma, and hodgkin's lymphoma.. . ... Eli Lilly And Company

11/23/17 / #20170334885

Pyrazole compounds

This invention relates to pyrazole compounds or pharmaceutically acceptable salts thereof. Compounds of this invention are inhibitors of methionine aminopeptidase 2 (metap2) and dipeptidyl peptidase-4 (dpp-4). ... Eli Lilly And Company

11/16/17 / #20170326128

Novel methyl-piperidine compounds useful for inhibiting microsomal prostaglandin e2 synthase-1

The present invention provides compounds of formula (1), or a pharmaceutically acceptable salt thereof, formula (1), where r, r1, and g are as described herein; methods of preparing the compounds; and use of the compounds to treat pain and/or inflammation associated with arthritis or osteoarthritis.. . ... Eli Lilly And Company

11/16/17 / #20170325480

Methods and formulations for reducing bovine emissions

The present disclosure provides methods and formulations for reducing ammonia and carbon dioxide emissions from a bovine using lubabegron, or a physiologically acceptable salt thereof. The present disclosure also provides bovine feed additives and bovine feed compositions.. ... Eli Lilly And Company

09/28/17 / #20170275356

Antibodies that bind il-23

. . The present invention provides an antibody that binds to the p19 subunit of human il-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. ... Eli Lilly And Company

09/21/17 / #20170267691

Erk inhibitors

The present invention provides thieno[2,3-c]pyrrol-4-one compounds that inhibit activity of extracellular-signal-regulated kinase (erk) and may be useful in the treatment of cancer.. . ... Eli Lilly And Company

09/14/17 / #20170259008

Rigid needle shield gripping cap assembly

A cap assembly mountable to a rigid shield around a needle of a syringe. The cap assembly includes a gripper component and a base cap. ... Eli Lilly And Company

08/31/17 / #20170246399

Sensing system for detecting a piston in a medical fluid container

A sensing system for determining a position of a plunger within a fluid container. The sensing system includes a light source, a light detector and a controller. ... Eli Lilly And Company

08/31/17 / #20170246166

1,2-benzothiazole compounds for the treatment of kidney disorders

The present invention provides 1,2-benzothiazole compounds particularly useful in the treatment of diabetic nephropathy and other chronic kidney disorders and other diabetic complications.. . ... Eli Lilly And Company

08/24/17 / #20170240532

Azetidinyloxyphenylpyrrolidine compounds

The invention provides certain azetidinyloxyphenylpyrrolidine compounds, particularly compounds of formula i, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula i to treat overactive bladder.. ... Eli Lilly And Company

08/24/17 / #20170239343

Porcine reproductive and respiratory syndrome vaccine virus

The present invention relates to modified, live porcine reproductive and respiratory syndrome viruses. Viruses were genetically analyzed and selected based on phylogenetic grouping for modification by repeated passage in tissue culture. ... Eli Lilly And Company

08/17/17 / #20170233410

A tetrahydropyrrolo[3,4-d][1,3]thiazine-derivative as bace inhibitor

. . The present invention provides a compound of formula i: which is crystalline. The compound of formula (i) is useful in the treatment of akzheimer's disease (bace inhibitor).. ... Eli Lilly And Company

08/17/17 / #20170233378

1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as aicarft inhibitors in the treatment of cancers

1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as aicarft inhibitors.. . ... Eli Lilly And Company

08/17/17 / #20170233373

Crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol

The invention provides crystalline (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyethyl]-4-(4-methoxy-3-{[1-(5-methylpyridin-2-yl)azetidin-3-yl]oxy}phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol, and pharmaceutical compositions thereof. The invention further provides methods of using this compound to treat overactive bladder.. ... Eli Lilly And Company

08/10/17 / #20170224929

Thermal locking mechanism for a medication delivery device

A medication injection device (2) includes a housing (4) and a needled syringe (8) supported by the housing. The needle syringe has a plunger (10) and a volume containing medication. ... Eli Lilly And Company

08/10/17 / #20170224926

Automatic medication injection device with visible indication of injecting progress

An automatic medication injection device (20) including injecting progress indicators (82-85) visible along a periphery of the device housing (23). The injecting progress indicators include a flag element (100) which is movable as a drive mechanism (60) of the device advances a sealing plunger (58) within a container of medication (50). ... Eli Lilly And Company

08/10/17 / #20170224702

Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor

The present invention provides a method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula i, or a pharmaceutically acceptable salt thereof; in combination with an effective amount of an anti-n3pglu abeta monoclonal antibody.. . ... Eli Lilly And Company

07/20/17 / #20170204171

Anti-n3pglu amyloid beta peptide antibodies and uses thereof

Antibodies to human n3pglu aβ, compositions comprising such n3pglu aβ antibodies, and methods of using such n3pglu aβ antibodies for the treatment of a disease characterized by deposition of aβ including clinical or pre-clinical alzheimer's disease, down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.. . ... Eli Lilly And Company

06/22/17 / #20170173013

Combination therapy for cancer

The present invention provides preparation of medicaments for use in treating and methods of treating non-small cell lung cancer in a patient comprising: [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3h-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in combination, as further described herein, with an anti-vegfr2 antibody, preferably, ramucirumab.. . ... Eli Lilly And Company

06/22/17 / #20170172992

Treatment of androgen deprivation therapy associated symptoms

The present invention provides a method of treating symptoms associated with androgen deprivation therapy comprising administering to a patient in need of such treatment an effective amount of a compound of formula i: [formula should be inserted here] or a pharmaceutically acceptable salt thereof.. . ... Eli Lilly And Company

06/15/17 / #20170165234

Gpr142 agonist compounds

The present invention provides compounds of the formula (ia) wherein r is selected from the group consisting of ch3, ch(ch3)2, ch2cn, ch2chf2, ch2cf3, (a), (b), (c), (d), (e), (f), ch2ch2och3, and ch2c(o)och(ch3)2; r1 is selected from the group consisting of cf3, ocf3, and cl; r2 is selected from the group consisting of h and f; or a pharmaceutically acceptable salt thereof.. . ... Eli Lilly And Company

06/08/17 / #20170156371

Enzymes for reduced immunological stress

Compositions suitable for oral administration to an animal comprising at least one immune stress-reducing enzyme in an amount effective to decrease the level of positive acute phase protein in an animal, increase the level of negative acute phase protein in an animal, and/or improve animal growth performance is provided, as are methods using such compositions. The compositions include animal feed compositions, liquid compositions other than animal feed, and solid compositions other than animal feed.. ... Eli Lilly And Company

05/04/17 / #20170121411

Vegfr2/ang2 compounds

The present invention relates to compounds that bind to human vascular endothelial growth factor receptor-2 (vegfr2) and human angiopoietin-2 (ang2), and may be useful for treating cancer, especially solid tumors driven by vegfr2 and ang2, including gastric, hepatocellular carcinoma, ovarian, colorectal, non-small cell lung, biliary tract, and breast cancers.. . ... Eli Lilly And Company

05/04/17 / #20170119751

Aurora a kinase inhibitor

The present invention provides an aminopyridine compound, or a pharmaceutically acceptable salt thereof, that inhibits aurora a and, therefore may be useful in treating cancer.. . ... Eli Lilly And Company

04/27/17 / #20170114115

Glucagon receptor agonists

The present invention relates to compounds with an extended duration of action at the glucagon receptor as compared to native glucagon. Specifically provided are glucagon receptor agonists with modifications to the structure of native glucagon introduced to selectively agonize the glucagon receptor over an extended period of time.. ... Eli Lilly And Company

04/27/17 / #20170112904

Glucagon receptor agonists

The present invention relates to compounds with an extended duration of action at the glucagon receptor as compared to native glucagon. Specifically provided are glucagon receptor agonists with modifications to the structure of native glucagon introduced to selectively agonize the glucagon receptor over an extended period of time.. ... Eli Lilly And Company

04/20/17 / #20170107278

Antibodies to tau and uses thereof

Monoclonal antibodies to human tau aggregate, compositions comprising such tau antibodies, and methods of using such tau antibodies for the treatment of neurodegenerative diseases including alzheimer's disease, progressive supranuclear palsy and pick's disease.. . ... Eli Lilly And Company

04/06/17 / #20170095613

Rotatable end of dose feedback mechanism

An injection device for injecting a medicament includes a housing, a dose setting member (20) movable to set a dose to be injected, and a signal part (7). The signal part rotates from a first rotational position to a second rotational position to increase loading on a spring or spring arm when a dose is set due to rotation of the dose setting member. ... Eli Lilly And Company

04/06/17 / #20170095468

Transdermal formulations of pergolide and uses thereof

This invention provides transdermal non-patch pergolide formulations useful for the treatment of disease in an equine. The invention also provides methods for treating a disease in an equine by administering a formulation of the invention to an equine.. ... Eli Lilly And Company

03/16/17 / #20170073403

Cgrp antibodies

The present invention provides human engineered calcitonin gene related peptide (cgrp) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (cgrp) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.. ... Eli Lilly And Company

03/09/17 / #20170066781

Compounds useful for inhibiting ror-gamma-t

The present invention provides novel ror gamma-t inhibitors and pharmaceutical compositions thereof:. . ... Eli Lilly And Company

03/09/17 / #20170066780

Inhibitors of ezh2

The present invention relates to compounds that inhibit activity of the histone lysine methyltransferase, enhancer of zeste homolog 2 (ezh2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors.. . ... Eli Lilly And Company

03/02/17 / #20170058033

Pd-l1 antibodies

The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (pd-l1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.. . ... Eli Lilly And Company

03/02/17 / #20170056478

Rapid-acting insulin compositions

The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.. . ... Eli Lilly And Company

02/09/17 / #20170037034

Jak1 inhibitors

. . . . The present invention relates to certain benzimidazole compounds, or pharmaceutically acceptable salts thereof, that inhibit janus kinase 1 (jak1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat certain types of cancer.. . ... Eli Lilly And Company








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Eli Lilly And Company in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Eli Lilly And Company with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###